Vittoria Bio appoints seasoned biotech leader as COO

US clinical-stage cell therapy developer Vittoria Biotherapeutics has announced that Keith Westby has joined the company as its inaugural chief operating officer (COO).

Mr Westby brings over two decades of biotechnology entrepreneurial experience and a proven track record of building successful organizations. In his role, Mr Westby will manage the advancement of Vittoria’s novel therapeutics into the clinic, including Vittoria’s lead program, VIPER-101, for the treatment of T-cell lymphoma.

“We’re thrilled to have Keith join our team. His impressive track record and dedication to the discovery and development of innovative treatments for challenging diseases will provide a crucial layer of expertise to Vittoria’s executive team as we initiate first-in-human studies for our lead program,” said Nicholas Siciliano, Vittoria’s chief executive. “We’re excited to partner with Keith on our mission to develop pioneering CAR-T therapies for indications with significant unmet medical needs,” he added.